Amylyx Pharmaceuticals (AMLX) Common Equity (2021 - 2026)

Amylyx Pharmaceuticals' Common Equity history runs 6 years deep, the most recent figure standing at $273.2 million for Q1 2026.

• On a quarterly basis, Common Equity rose 35.62% year-over-year to $273.2 million in Q1 2026; TTM through Mar 2026 was $273.2 million, a 35.62% increase from a year earlier, with the FY2025 full-year figure at $305.3 million, up 85.27% from the prior year.
• Common Equity slipped to $273.2 million in Q1 2026 per AMLX's latest filing, from $305.3 million in the prior quarter.
• Across five years, Common Equity topped out at $433.4 million in Q4 2023 and bottomed at $144.0 million in Q3 2022.
• The 5-year median for Common Equity is $273.2 million (2026), against an average of $278.6 million.
• Across the five-year window, Common Equity surged 398.83% in 2022 and sank 61.99% in 2024, its largest moves.
• Year by year, Common Equity stood at $340.6 million in 2022, then grew by 27.25% to $433.4 million in 2023, then sank by 61.99% to $164.8 million in 2024, then jumped by 85.27% to $305.3 million in 2025, then fell by 10.52% to $273.2 million in 2026.
• Per Business Quant, the three latest AMLX Common Equity figures stand at $273.2 million (Q1 2026), $305.3 million (Q4 2025), and $332.0 million (Q3 2025).